TCMP
ABBV icon

Thrive Capital Management (Pennsylvania)’s AbbVie ABBV Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Buy
1,905
+108
+6% +$23.2K 0.09% 130
2026
Q1 		$391K Sell
1,797
-196
-10% -$43.5K 0.09% 135
2025
Q4 		$455K Buy
1,993
+189
+10% +$43.1K 0.1% 135
2025
Q3 		$418K Buy
1,804
+5
+0.3% +$1.02K 0.11% 135
2025
Q2 		$334K Buy
1,799
+370
+26% +$68.8K 0.1% 141
2025
Q1 		$299K Buy
+1,429
New +$278K 0.18% 98
2024
Q4 		– Sell
-1,669
Closed -$330K – 97
2024
Q3 		$330K Sell
1,669
-11,081
-87% -$2.07M 0.16% 146
2024
Q2 		$2.19M Buy
12,750
+5,085
+66% +$842K 1% 20
2024
Q1 		$1.4M Buy
7,665
+4,583
+149% +$790K 0.74% 20
2023
Q4 		$478K Sell
3,082
-97
-3% -$14.1K 0.26% 62
2023
Q3 		$474K Sell
3,179
-6
-0.2% -$881 0.26% 63
2023
Q2 		$429K Sell
3,185
-292
-8% -$42.8K 0.24% 69
2023
Q1 		$549K Buy
3,477
+145
+4% +$22.2K 0.35% 58
2022
Q4 		$539K Buy
3,332
+99
+3% +$15.2K 0.35% 56
2022
Q3 		$434K Buy
3,233
+706
+28% +$101K 0.29% 61
2022
Q2 		$387K Buy
2,527
+368
+17% +$56.2K 0.27% 61
2022
Q1 		$350K Sell
2,159
-5,232
-71% -$760K 0.21% 64
2021
Q4 		$1M Sell
7,391
-7,794
-51% -$921K 0.65% 40
2021
Q3 		$1.64M Buy
15,185
+712
+5% +$81.4K 1.21% 21
2021
Q2 		$1.63M Buy
14,473
+5,121
+55% +$577K 1.27% 19
2021
Q1 		$1.01M Buy
9,352
+2,665
+40% +$285K 0.95% 26
2020
Q4 		$716K Buy
+6,687
New +$643K 0.76% 30

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s ABBV Position: Q2 2026 in Review

Thrive Capital Management (Pennsylvania) increased its AbbVie (ABBV) stake by 6% in Q2 2026, buying an estimated $23.2K and bringing the position to 1,905 shares worth $479K. The position accounts for 0.09% of the portfolio, ranked #130.

Thrive Capital Management (Pennsylvania) first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $2.19M in Q2 2024. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Thrive Capital Management (Pennsylvania) held 1,905 shares of AbbVie worth $479K as of Q2 2026.
  • Thrive Capital Management (Pennsylvania) bought 108 AbbVie shares in Q2 2026, an estimated $23.2K.
  • AbbVie made up 0.09% of Thrive Capital Management (Pennsylvania)'s portfolio in Q2 2026, its #130 holding.
  • Thrive Capital Management (Pennsylvania) first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • Thrive Capital Management (Pennsylvania)'s AbbVie position peaked at $2.19M in Q2 2024.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2026, filed 5 Aug 2026.